IOVA Profitability Analysis: Margins, Return on Capital, Free Cash Flow, and More - Iovance Biotherapeutics Inc

Watchlist Manager

Watchlist

Price: 9.69 USD -34.57% Market Closed

Market Cap: $4.3B

	Iovance Biotherapeutics Inc NASDAQ:IOVA	US
	GlobeStar Therapeutics Corp OTC:GSTC	US
A	Accenture PLC SWB:CSA	IE

Profitability Summary

Iovance Biotherapeutics Inc's profitability score is 19/100. We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.

Healthy Gross Margin

48%

Negative 3Y Average Gross Margin

-134%

Gross Margin is Increasing

-800% > 48%

Negative Operating Margin

-93%

Negative 3Y Average Operating Margin

-6 022%

Operating Margin is Increasing

-62 866% > -93%

Negative Net Margin

-89%

Negative 3Y Average Net Margin

-5 800%

Net Margin is Increasing

-60 983% > -89%

Negative Free Cash Flow Margin

-91%

Negative 3Y Average Free Cash Flow Margin

-5 106%

Free Cash Flow Margin is Increasing

-53 142% > -91%

Negative ROE

-40%

Negative 3Y Average ROE

Negative 3Y Average ROIC

-85%

ROIC is Increasing

-140% > -51%

View All

Hide

Collapse

19 / 100

Profitability
Score

We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.